Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith W Pratz

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|December 23, 2024
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1Keith W Pratz
Hematology. American Society of Hematology. Education Program|December 9, 2022
Optimizing outcomes in secondary AMLAndrew Matthews, Keith W Pratz
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid LeukemiaHany Elmariah, Keith W Pratz
Blood|November 23, 2016
How I treat FLT3-mutated AMLKeith W Pratz, Mark Levis
Current Drug Targets|April 8, 2010
Bench to bedside targeting of FLT3 in acute leukemiaKeith W Pratz, Mark J Levis
Leukemia & Lymphoma|June 3, 2017
Acute myeloid leukemia in the elderly: therapeutic options and choiceJonathan A Webster, Keith W Pratz
Current Opinion in Hematology|January 29, 2014
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Keith W Pratz, Selina M Luger
American Journal of Hematology|February 17, 2025
Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted AgentsKeith W Pratz, Harry P Erba
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total TherapyAlexander E Perl, Keith W Pratz
Leukemia & Lymphoma|March 11, 2017
Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progressionMelanie T Rebechi, Keith W Pratz
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|December 23, 2024
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1Keith W Pratz
Hematology. American Society of Hematology. Education Program|December 9, 2022
Optimizing outcomes in secondary AMLAndrew Matthews, Keith W Pratz
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid LeukemiaHany Elmariah, Keith W Pratz
Blood|November 23, 2016
How I treat FLT3-mutated AMLKeith W Pratz, Mark Levis
Current Drug Targets|April 8, 2010
Bench to bedside targeting of FLT3 in acute leukemiaKeith W Pratz, Mark J Levis
Leukemia & Lymphoma|June 3, 2017
Acute myeloid leukemia in the elderly: therapeutic options and choiceJonathan A Webster, Keith W Pratz
Current Opinion in Hematology|January 29, 2014
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Keith W Pratz, Selina M Luger
American Journal of Hematology|February 17, 2025
Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted AgentsKeith W Pratz, Harry P Erba
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total TherapyAlexander E Perl, Keith W Pratz
Leukemia & Lymphoma|March 11, 2017
Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progressionMelanie T Rebechi, Keith W Pratz
Pageof 8